Comparing of Aeterna Zentaris Inc. (AEZS) and Catalyst Biosciences Inc. (NASDAQ:CBIO)

This is a contrast between Aeterna Zentaris Inc. (NASDAQ:AEZS) and Catalyst Biosciences Inc. (NASDAQ:CBIO) based on their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aeterna Zentaris Inc. 25.67M 2.53 8.83M 0.53 7.08
Catalyst Biosciences Inc. N/A 18234.30 30.05M -3.01 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Aeterna Zentaris Inc. and Catalyst Biosciences Inc.


Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Aeterna Zentaris Inc. 34.40% 137.5% 29.7%
Catalyst Biosciences Inc. 0.00% -22.7% -21.8%

Risk & Volatility

Aeterna Zentaris Inc. has a beta of 1.23 and its 23.00% more volatile than Standard & Poor’s 500. Competitively, Catalyst Biosciences Inc.’s beta is 2.2 which is 120.00% more volatile than Standard & Poor’s 500.


The Current Ratio and Quick Ratio of Aeterna Zentaris Inc. are 3.6 and 3.3 respectively. Its competitor Catalyst Biosciences Inc.’s Current Ratio is 40.2 and its Quick Ratio is 40.2. Catalyst Biosciences Inc. can pay off short and long-term obligations better than Aeterna Zentaris Inc.

Insider and Institutional Ownership

Institutional investors held 21.4% of Aeterna Zentaris Inc. shares and 74.9% of Catalyst Biosciences Inc. shares. About 0.6% of Aeterna Zentaris Inc.’s share are held by insiders. Insiders Competitively, held 0.3% of Catalyst Biosciences Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aeterna Zentaris Inc. -9.57% -1.31% 23.53% 110% 122.35% 28.57%
Catalyst Biosciences Inc. -2.61% -2.5% -18.54% -20.5% -67.41% 8.62%

For the past year Aeterna Zentaris Inc.’s stock price has bigger growth than Catalyst Biosciences Inc.


Aeterna Zentaris Inc. beats Catalyst Biosciences Inc. on 8 of the 10 factors.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companyÂ’s product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.